# Black Diamond Therapeutics, Inc. (BDTX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $106M  
**Price:** $1.85 (-2.63%)

> Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers. These therapies aim to address a broad spectrum of tumors, overcome resistance mechanisms, minimize wild-type mediated toxicities, and achieve brain penetrance for treating central nervous system diseases, including brain metastases and primary brain tumors. The company's lead candidate, silevertinib (BDTX-1535), is a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor advancing in a Phase 2 trial for frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations and in trials for glioblastoma (GBM) with EGFR alterations. Black Diamond Therapeutics has also licensed BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting RAF/RAS-mutant solid tumors, to Servier for further development. Headquartered in Cambridge, Massachusetts, and founded in 2014, the company focuses on precision oncology to meet unmet needs in mutation-driven cancers.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $70M | — | $13M | $22M | — |
| 2024 | — | — | -$79M | -$70M | — |
| 2020 | — | — | -$70M | -$67M | — |
| 2019 | — | — | -$29M | -$35M | — |
| 2018 | — | — | -$9M | -$9M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $143M | $31M | $112M | $21M | — |
| 2024 | $123M | $39M | $83M | $36M | — |
| 2020 | $330M | $22M | $308M | $35M | — |
| 2019 | $158M | $5M | -$47M | $155M | — |
| 2018 | $52M | $7M | -$16M | $52M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $30M | — | — |
| 2024 | -$62M | — | -$62M |
| 2023 | -$67M | $33,000 | -$67M |
| 2022 | -$85M | $192,000 | -$85M |
| 2021 | -$100M | $3M | -$103M |
| 2020 | -$52M | $142,000 | -$52M |
| 2019 | -$25M | $21,000 | -$25M |
| 2018 | -$8M | $76,000 | -$9M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BDTX)